Gerresheimer AG Stock (DE000A0LD6E6): BaFin review widens as the accounting overhang persists

Gerresheimer remains under pressure after reports that Germany's BaFin widened its review of possible accounting issues. The stock was last quoted at 24.40 euros on Tradegate, after a turbulent stretch in which the company also faced delayed reporting.

By AD HOC NEWS - Companies & Analysis Desk Team | June 10, 2026

Gerresheimer is in focus after reports that Germany's BaFin widened its review of possible accounting irregularities, while the stock was last quoted at 24.40 euros on Tradegate on June 10, 2026. The latest reporting keeps the German packaging and drug-delivery company under a cloud at a time when investors are still waiting for clean, audited numbers.

Why the stock is in focus today

According to Finanztrends, BaFin identified additional possible accounting errors, including questions around lease liabilities, the useful lives used for capitalized development costs, and unrecognized impairments. The same report says APAS, Germany's audit oversight body, opened proceedings against auditor KPMG, adding another layer of scrutiny to a process that has already forced Gerresheimer to push back several disclosures.

The reporting delay matters because the company has repeatedly shifted the timetable for its audited figures, and the market is now watching whether Gerresheimer can meet the revised deadline of September 30, 2026. Finanztrends also said the company's annual general meeting and first-quarter update were canceled, which reinforces the view that this is no longer just a routine timing issue.

There is also a balance-sheet angle that investors cannot ignore. Finanztrends reported that the Advanced Technologies segment alone carries a book value of almost 197 million euros, which helps explain why any impairment review could matter well beyond a single line item.

Even with the accounting uncertainty, the company has not walked away from its 2026 operating outlook. Finanztrends said Gerresheimer still targets revenue of 2.3 billion to 2.4 billion euros and an adjusted EBITDA margin of 18% to 19%, although those goals remain tied to the outcome of the audit and lender discussions.

The stock's market backdrop is weak by any standard. Finanztrends said Gerresheimer shares were down 49.5% over the past year, and the company was removed from the SDAX in April 2026. That combination of index fallout and unresolved reporting issues is keeping the name in the market's penalty box.

Gerresheimer stock snapshot

• Name: Gerresheimer AG
• Industry: Pharmaceutical packaging and drug delivery systems
• Headquarters: Duesseldorf, Germany
• Core markets: Pharma packaging, drug delivery systems, medical devices, specialty glass and plastic solutions
• Revenue drivers: Primary packaging for pharmaceuticals, complex drug-delivery devices, and specialty packaging technologies
• Listing: Listed in Germany; no verified NYSE or Nasdaq listing found in the available sources. The company is included in the MDAX and trades under ISIN DE000A0LD6E6.
• Trading currency: Euro

This article was created with a.i. assistance and editorially reviewed. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.